PGT-A, Preimplantation Genetic Testing for Aneuploidy
Our team at Access Genomics helps you build better treatment plans by providing much needed answers.
Following a non-invasive embryo trophectoderm (TE) biopsy, a report is provided with a complete data set for each embryo’s biopsied cells. Without a lengthy waiting period, patients receive accurate information from their fertility physician. The screening findings report assists with streamlining treatment plan options, allowing you to deliver better outcomes to your IVF patients.
- Clear and accurate results – low error rate and deeper sequencing with Next Generation Sequencing
- Detailed reports – showing variants of DNA for all chromosomes
- Quick turnaround time – 4 days from receipt of biopsy sample
- Reduced costs for patient – possibility of reduced number of IVF cycles
- Better patient care
- may reduce number of IVF cycles per patient, and number of retrievals, reducing need for stimulating medications (e.g. gonadotropins).
- if multiple euploid embryos identified, they may be stored for future implantation.
- healthier outcomes with elective single embryo transfer (eSET)
Step 1: In vitro fertilization [introduction of the sperm and egg] occurs in your fertility clinic’s embryology lab and is monitored for viable embryonic development.
Step 2: The viable embryo blastocyst’s TE cells are biopsied on DAY 5 by your clinic’s embryology team and the blastocyst is cryopreserved. The biopsied TE cells are sent to our genomics lab for PGT-A screening. Refer to ESHRE TE Biopsy methodology.
Step 3: We screen the biopsied TE cells and report the findings to your clinic, identifying any euploid, euploid mosaic and/or aneuploid embryos.
Step 4: Embryo selection with your patient. On discussing the embryo selection for transfer with your patient, the PGT-A findings, along with zygote scoring and the morphology of the embryo should all be combined to inform your discussion. (You may or may not wish to have your patient speak with a genetic counsellor about the results, particularly if mosaicism is involved.)
Step 5: The healthy embryos are thawed and transferred (healthy embryos not transferred can be frozen for future use).
Success rates speak for themselves
Patients are looking to increase their chances of pregnancy and a healthy baby being born, decrease the number of IVF cycles, and decrease their risk of miscarriage.
Through PGT-A, you can offer a proven way to improve Implementation rates.
Next Generation Sequencing (NGS)
Access Genomics uses the most advanced whole genome sequencing tool called Next Generation Sequencing (NGS).
NGS offers unrivalled depth of feedback in screening which empowers you and your fertility physician to make better informed decisions regarding embryo selection, which in turn may increase your chance of IVF success.
PGT-A is unanimously recommended by Canadian and International regulating bodies
The Preimplantation Genetic Diagnosis International Society (PGDIS) states that “Indeed, using these methods (preimplantation genetic diagnosis for aneuploidy, PGD-A, or preimplantation genetic screening, PGS) has now been shown in numerous studies to improve implantation, pregnancy and live birth rates (per embryo transferred) and reduce miscarriage rates.”
PGDIS Newsletter, July 19, 2016 – PGDIS Position Statement on Chromosome Mosaicism and Preimplantation Aneuploidy Testing at the blastocyst stage.”
The Society of Obstetricians and Gynaecologists of Canada (SOGC) states that “Preimplantation genetic screening […] increases implantation rates and improves embryo selection in IVF cycles in patients ‘with a good prognosis’.”
(Dahdouh et al., (2015) J. Obstet. Gynaecol. Can., 37(5):451-463).
A recent study on obstetrical and neonatal outcomes published by the American Journal of Obstetrics & Gynaecology (AJOG) states “By culturing embryos to the blastocyst stage, performing a trophectoderm biopsy,
and amplifying DNA … on each chromosome, a single euploid blastocyst with high reproductive potential can be selected for transfer. This paradigm eliminates the risk of multizygotic multiple gestation and increases the chance for a healthy, term singleton delivery without requiring patients to undergo an increased number of failed cycles. The improved obstetrical and neonatal outcomes suggest this approach may become the standard of care for infertile couples requiring IVF.”
Eric J. Forman et al., February 2014, American Journal of Obstetrics & Gynecology, 157.e6
“A study performed at Reproductive Medicine Associates
of New Jersey demonstrated that TE biopsy is safer than biopsying a single cell on day 3, and it’s also more accurate. A separate collection of cells called the inner cell mass (ICM) becomes the actual embryo, and ultimately the baby, and is not touched by the embryologist when TE biopsy is performed.”
Eric Forman, MD, The Problem of Mosaic Embyros in IVF, https://www.fertilityiq.com/pgs- and-ccs-genetic-testing/the-problem-of-mosaic-embryos-in-ivf
By enhancing embryo selection with a validated method of aneuploidy screening, a single euploid embryo with high reproductive potential can be selected for transfer. Using this approach, eSET (elective single embryo transfer) can be performed without compromising delivery rates and improving the chance of having a healthy, term singleton
delivery after in vitro fertilization.”
American Journal of Obstetrics and Gynaecology 2014;210:157.e1-6.